tbuckley/cabot-search huggingface dataset:
A multicentre, randomised, double-blind, parallel-group, placebo-controlled trial of apatinib in local progressive or metastatic radioactive iodine-refractory differentiated thyroid cancer
Authors: Y. Lin, S. Qin
Journal: Annals of Oncology (2017)

Background: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a big challenge in the management of thyroid cancer. Sorafenib and lenvatinib are the 2 FDA-approved tyrosine kinase inhibitors (TKIs), which might not be affordable for most of the Chinese patients (pts). Apatinib is an oral TKI targeting VEGFR-2, with a patient assistance program available in China. It achieved a quick Tg decline of 21% 2 weeks later and an objective response rate (ORR) of 90%, showing promising efficacy in RAIR-DTC (Lin et al, ATA 2016, Short Call Poster 65; Lin et al, Oncotarget, Epub Feb. 02, 2017). Thus, this study aimed to further evaluate the efficacy and safety of apatinib in treating RAIR-DTC. Trial design: This study is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III trial in China. Adult pts with locally advanced or metastatic RAIR-DTC are eligible. The inclusion criteria include at least one measurable lesion; disease progression within the past 12 months; and ECOG PS 0–2. Pts are defined as RAIR-DTC if they have target lesion(s) without iodine uptake, received one RAI treatment (≥3.7 GBq [≥100 mCi]) but progressed within the past 12 months, received two RAI treatments or more with a time interval of less than 12 months and progressed at least 12 months later), or received cumulative RAI activity over 22.2 GBq (≥600 mCi). Previous targeted therapy is not allowed. Enrolled patients will be randomly assigned to receive apatinib (500 mg qd) and placebo, respectively. Four weeks is defined as one cycle. Dose increase to 750 mg and dose reduction to 250 mg are allowed. The primary endpoint is progression free survival. The secondary endpoints include disease control rate, ORR, duration of response, changes in serum Tg and TgAb concentration, quality of life, and safety. A multiple Cox proportional hazards model is used to evaluate the hazard ratios after adjusting iodine uptake, metastatic lesion site, gender, and age. 118 pts will be recruited assuming a 106.9% increase in median PFS in the apatinib arm compared with the placebo arm. As of 2nd May 2017, 3 eligible patients have been enrolled. Clinical trial identification: NCT03048877 (Release date: February 7, 2017) Legal entity responsible for the study: Yansong Lin Funding: None Disclosure: All authors have declared no conflicts of interest.
COMMITMENT OF THE INSANE IN THE STATE OF NEW YORK.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The clearance rate of chylomicron retinyl ester from plasma can be used to distinguish rats with cirrhosis from those with portacaval shunt
Authors: T Kasai
Journal: Hepatology (1993)

Effects of carbon tetrachloride treatment and portacaval shunt surgery on exogenous chylomicron retinyl ester clearance from rat plasma were analyzed assuming three-compartment model kinetics. In rats with cirrhosis and in those with Eck fistulas, the relative pool size of compartment 2 decreased (0.20 and 0.36, respectively) compared with controls (0.82). The relative mass of compartment 3 significantly increased in rats with cirrhosis (1.55) or Eck fistula (0.19) compared with control rats (0.11). The cirrhotic and Eck fistula groups were indistinguishable on the basis of these parameters and on the basis of indocyanine green test values. However, the cirrhosis and Eck fistula groups differed clearly from each other with respect to fractional efflux rate constants (l2,l3), where the constant l2 is from compartment 2 and the l3 is from compartment 3. Both values decreased in cirrhotic rats, suggesting that the hepatic uptake of chylomicron retinyl esters was impaired by carbon tetrachloride. On the other hand, Eck fistula rats did experience dramatic increases in l3, implying that the hepatic uptake of chylomicron retinyl esters from compartment 3 was enhanced by portacaval shunting. Elevation of the plasma estrogen level observed in Eck fistula rats may be responsible for the induction of low-density lipoprotein receptors on hepatocytes and for the subsequent enhancement of l3. These results suggest that a three-compartment model of plasma retinyl ester disappearance kinetics gives important quantitative information about hepatic function. Clinical application of the chylomicron retinyl ester clearance test is discussed for estimating hepatic function reserves and for differential diagnosis of portal hypertension. (HEPATOLOGY 1993;17:125–130.)
Thyroid hormone metabolism and thyroid diseases in chronic renal failure
Authors: E. M. Kaptein
Journal: Endocrine Reviews (1996)

END-STAGE renal disease (ESRD) is a relatively common nonthyroidal illness, which induces significant morbidity and mortality (1). In the United States, more than 220,000 patients were being dialyzed for ESRD in 1992, with an 8–9% annual increase in frequency over the last 10 years (1, 2). This rising incidence of ESRD reflects improved survival rates of ESRD patients and increasing age of the general population, with the greatest increase in ESRD frequency being in people over 64 yr of age (2). ESRD is a moderate to severe nonthyroidal illness and, as such, frequently alters thyroid hormone metabolism (3). In addition to metabolic and endocrine derangements induced by ESRD, these patients frequently have a multitude of nonrenal nonthyroidal disorders that affect thyroid hormone metabolism, including diabetes mellitus (1), infections (1), and malnutrition (4–6), and they are treated by a variety of pharmacological agents. Knowledge of alterations of thyroid hormone metabolism in euthyroid ESRD patients is required to accurately diagnose and treat concurrent hypothyroidism and hyperthyroidism.
Precipitate from Cold-thawed Plasma Potent in Therapy for Hemophiliacs
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Section 70.—Appendix I: Criteria for Diagnosis and Classification of Rheumatic Diseases
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LEUKAEMIA CUTIS
Authors: A. MURRAY STUART
Journal: British Journal of Dermatology (1943)

Journal Article LEUKAEMIA CUTIS Get access A. MURRAY STUART A. MURRAY STUART Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 55, Issue 3, 1 March 1943, Pages 65–68, https://doi.org/10.1111/j.1365-2133.1943.tb10741.x Published: 01 March 1943
Consensus conference. Lowering blood cholesterol to prevent heart disease
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long‐term treatment of refractory thrombocytopenia in a patient with wiskott‐aldrich syndrome with vincristine, immunoglobulin, and methylprednisolone
Authors: Guy Young, Anne L. Angiolillo
Journal: American Journal of Hematology (1999)

We report a child with Wiskott-Aldrich syndrome with severe, refractory, symptomatic thrombocytopenia who achieved an excellent response to combination therapy with vincristine 1.5 mg/m2 × 1 day, intravenous immunoglobulin 1 g/kg × 3 days, and methylprednisolone 25 mg/kg × 3 days (VIM) for 7 years after failing multiple treatments. He did not have a histocompatible donor for bone marrow transplantation. When the patient ceased to respond to this regimen, he was rescued with pulse dexamethasone. Vincristine, immunoglobulin, and methylprednisolone might serve as a novel treatment option for the patient with refractory thrombocytopenia. Our patient had a sustained remission of symptomatic thrombocytopenia without toxicity. Furthermore, pulse dexamethasone might be an alternative treatment option to which patients with Wiskott-Aldrich syndrome may respond. Am. J. Hematol. 62:183–185, 1999. © 1999 Wiley-Liss, Inc.
Pulmonary Haemosiderosis
Authors: P. Ellman, A. Gee
Journal: BMJ (1951)

MESS TRICK " AND " FAINTING LARK " brain blood vessels.Compression of the chest causes the victim to perform an involuntary Valsalva manceuvre, which in the presence of peripheral dilatation is sufficient to reduce effective blood pressure and consequently cerebral blood flow to levels which cause unconsciousness.The " fainting lark " consists in a subject's squatting on his haunches and hyperventilating for 20 breaths, rising rapidly to the erect posture, and immediately performing the Valsalva manceuvre.Consciousness is lost within a few seconds.The mechanism is the same as in the " mess trick," with the added factor of the fall in blood pressure produced by rising from the squatting posture.
The Pathological Gall-Bladder Roentgenologically Considered.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computerized Cranial Tomography
Authors: Harvey V. Fineberg
Journal: JAMA (1977)

The effect of computerized cranial tomography (CCT) on physicians' diagnostic and therapeutic plans in 194 patients scanned consecutively during a 17-day period at the Massachusetts General Hospital was studied. Use of CCT substantially decreased the perceived need for other neurodiagnostic tests in this patient population. There was a reduction of at least 41% in radionuclide scans, 52% in angiograms, and 73% in pneumoencephalograms compared to the needs projected had CCT not been available. Therapy was altered after 37 scans in 36 patients (19% of those examined): new treatment was begun after 15 scans, previously planned therapy became more precise after 9 scans, treatment was found to be unnecessary after 7 scans, and treatment was abandoned as worthless after 6 scans. (<i>JAMA</i>238:224-227, 1977)
Spontaneous Closure of Ventricular Septal Defects
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Comments
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Da Costa's Syndrome (or Effort Syndrome). Lecture II
Authors: P. Wood
Journal: BMJ (1941)

Vasomotor Disturbances: 1. Tachycardia It is this sign above all others which has drawn attention to the heart, yet it is one of the commonest psychosomatic effects, occurring in every one of us under the influence of sufficient emotion.It h1as been recorded by all observers, and in my ownI series of 200 cases the pulse rate averaged 82 beats per minute (48 to 136) during casual examination in the day-time, compared -with 66 beats per minute (48 to 100) in 50 controls.During sleep, however, it is normal, averaginig 60 to 65 in Huine's series (1918).It is cus- tomary to speak of the great lability of the pulse, which is' said to accelerate unduly with change of posture, with effort, and with adrenaline.The evidence for this, how- ever, is open to criticism.-Statements declaring that there is undue acceleration of the pulse rate on change of posture may be challenged directly, because the published figures do not show it, even those given by authors who make this yery statement.Thus in 36 children with " effort syndrome " Bass and Wessler (1913) found the difference between the lying anid standing pulse rates to average 7 beats per minute, which was the exact figure obtained by Lincoln (1928) in 320 controls aged between 3 and 13.In adult patients published figures are well within published control figures; they are hardly worth quoting, because little attention has been paid to the behaviour of the pulse on standing up.Douglas and I have found that the initial acceleration lasts for but nine to fifteen seconds in about two-thirds of patients and controls, and is followed by abrupt slowing.It is therefore necessary to count the pulse for the first ten seconds only, after the patient stands up, if the true speed at this time is wanted.In comparing patients with controls we took three readings: (1) during the first ten seconds as described; (2) during the second quarter-minute; (3) at the eind of the first minute.The results are recorded in T'able IX, and show no essential difference.It is coIn- TABLE IX.-Rise of Pulse Rate with Change of Posture No. of Rise in Rise in Rise at End Cases First 10 Sec.Second First Min.M..1 20 21 (6-40) 7.8 (-4 -20) Da Costa's syndrome q 20 24 (8-40) 9 (0 -40) 9 (0-42) 25 8 (0-28) Controls r 22 24 (6-40) 7.5 (0 -24) 'V 40 8 (0-24)
In Vitro Absorption of Some o-Phthalate Diesters through Human and Rat Skin
Authors: Robert C. Scott, Paul H. Dugard, John D. Ramsey, Christopher Rhodes
Journal: Environmental Health Perspectives (1987)

The absorption of undiluted phthalate diesters [dimethyl phthalate (DMP), diethylphthalate (DEP), dibutyl phthalate (DBP) and di-(2-ethylhexyl)phthalate (DEHP)] has been measured in vitro through human and rat epidermal membranes. Epidermal membranes were set up in glass diffusion cells and their permeability to tritiated water measured to establish the integrity of the skin before the phthalate esters were applied to the epidermal surface. Absorption rates for each phthalate ester were determined and a second tritiated water permeability assessment made to quantify any irreversible alterations in barrier function due to contact with the esters. Rat skin was consistently more permeable to phthalate esters than the human skin. As the esters became more lipophilic and less hydrophilic, the rate of absorption was reduced. Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin. Although differences were noted between species, the absolute rates of absorption measured indicate that the phthalate esters are slowly absorbed through both human and rat skin.
Increasing age and survival after bone marrow transplant
Authors: L. Brinch
Journal: JAMA (1993)

<h3>In Reply.</h3> —The conclusion that age does not adversely affect outcome after allogeneic bone marrow transplantation in patients with leukemia is based on our findings in patients with early and intermediate disease. In these groups, the leukemia-free survival rate (95% confidence interval) at 2 years was 57% (37% to 75%) and 25% (6% to 65%), respectively. This is not significantly different from the corresponding figures of 51% (47% to 55%) and 32% (26% to 39%) in patients 30 to 39 years of age. The small numbers of subjects 50 years and older with advanced leukemia limited our ability to detect differences in this group. This we indicated in our report. Based on Karnofsky scores, duration of disease, and absence of infection prior to transplant, we found no evidence of a selection bias in transplant recipients older than 50 years compared with younger patients. However, transplant recipients are a select group,
Cholesterol Redux
Authors: Basil M. Rifkind
Journal: JAMA (1990)

In the 4 years sinceThe Journal's last issue focusing on cholesterol, evidence of the crucial role of serum cholesterol levels in atherosclerosis has continued to accumulate. At the same time, great progress has been made in clinical and population-based efforts to confront this major health risk. The leadership of government health agencies, medical organizations, and the media in cholesterol education, much of it coordinated through the mechanism of the National Cholesterol Education Program, has brought cholesterol management from an arcane backwater to a matter of public policy. Impressive scientific documentation naturally accompanies this newfound respectability. Of particular note are the outcomes of six controlled angiographic trials of total cholesterol or low-density lipoprotein cholesterol lowering with or without high-density lipoprotein cholesterol increase<sup>1-7</sup>; two of these studies are described in this issue. These provide evidence that treatment will alter the natural history of atherosclerotic lesions—progression of lesions can be